Wockhardt Pharma is in the spotlight today with two major

Wockhardt Pharma is in the spotlight today with two major developments: strong Q4 FY26 earnings showing a sharp profit surge, and a ₹16 crore customs penalty over an API classification dispute. The stock is trading bullish despite regulatory headwinds. Financial Performance (Q4 FY26) Total Income: ₹965 crore (up 8.67% QoQ, 29.88% YoY) Operating Profit: ₹165 crore (+68.37% QoQ) Net Profit: ₹166 crore (+181.36% QoQ) Operating Margin: 17.1% EPS: ₹9.03 (vs ₹4.17 last quarter, vs -₹5.80 last year) Stock Price Today: Around ₹1,951.60 on BSE (+3.79%) and ₹1,947.70 on NSE (+3.49%) Trend: Long-term bullish, short-term moderately bullish Q1 FY27 (June 2026): Net profit of ₹107 crore (vs ₹108 crore loss last year). Revenue: ₹929 crore (+26% YoY). EBITDA: ₹188 crore (+86% YoY, margin 20.2%). Biosimilars: Sales doubled to ₹236 crore. New Drug Approval: Zaynich, a novel antibiotic, approved in US & India. Peak sales potential projected at $1.5–2 billion. Launch planned in US and India by early 2027. Antibiotic Academy: Initiative to combat antimicrobial resistance, fostering dialogue among healthcare professionals